Alembic Pharmaceuticals has received approval from the U.S. Food and Drug Administration (USFDA) for a generic ophthalmic formulation, strengthening its presence in the regulated U.S. market. The approval allows the company to manufacture and market the eye treatment in the United States, expanding its specialty product portfolio. Industry analysts view the development as a positive step for Alembic’s growth strategy, particularly as demand for cost-effective eye care therapies continues to rise.